DEFA14A: Repare Therapeutics Inc. to Hold Annual Meeting on June 17, 2024

Repare Therapeutics Inc. will hold its annual meeting of shareholders on June 17, 2024, to elect directors, approve executive compensation, and appoint an independent accounting firm.

Summary

• Repare Therapeutics Inc. is holding its Annual Meeting of Shareholders on June 17, 2024.
• Shareholders of record as of April 19, 2024, are eligible to vote.
• The meeting will include the election of two Class I directors, Susan M. Molineaux, Ph.D. and Ann D. Rhoads, each to hold office until the Annual Meeting in 2027.
• Shareholders will also vote on an advisory basis regarding the compensation of named executive officers.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be voted on, with authorization for the board to fix their remuneration.
• The meeting will be held live via the internet, and pre-registration is required at www.proxydocs.com/RPTX.
• Shareholders can access proxy materials and vote online at www.proxydocs.com/RPTX using their 12-digit control number.
• The proxy materials are also available at www.sedarplus.ca.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral sentiment. It focuses on routine corporate governance matters.

Positives

• Shareholders have multiple options for accessing proxy materials and voting, including online and by mail.
• The board of directors is recommending a vote for each of the director nominees and for proposals 2 and 3.

Future Outlook

The document outlines the agenda for the upcoming annual meeting, focusing on governance and operational matters for the coming year.

Industry Context

This is a standard proxy statement related to the annual meeting of shareholders, a routine event for publicly traded companies.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting.
• The outcome of the votes will impact the composition of the board and the selection of the accounting firm.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will proceed with the Annual Meeting on June 17, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Shareholders, Repare Therapeutics, Directors, Executive Compensation, Ernst & Young, Accounting Firm